Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Berciano-Guerrero

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Medicinal Chemistry|July 22, 2014
Nanoparticles in melanomaM A Berciano-Guerrero, A Montesa-Pino, G Castaneda-Penalvo, et al.
Current Medicinal Chemistry|July 27, 2012
Current trends in the chemotherapy of colorectal cancerM A Berciano-Guerrero, J C Villa-Guzmán, R Acosta-Guerrero, et al.
Journal of Biological Regulators and Homeostatic Agents|October 5, 2019
Pseudovitelliform maculopathy secondary to BRAF and MEK inhibitors in a patient with metastasic melanomaC Alba-Linero, C Rocha De Lossada, A S Delgado-Fernández, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic MelanomaA Arance, M-A Berciano-Guerrero, J Guo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 26, 2020
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practiceE Pérez-Ruiz, J Jiménez-Castro, M-A Berciano-Guerrero, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Medicinal Chemistry|July 22, 2014
Nanoparticles in melanomaM A Berciano-Guerrero, A Montesa-Pino, G Castaneda-Penalvo, et al.
Current Medicinal Chemistry|July 27, 2012
Current trends in the chemotherapy of colorectal cancerM A Berciano-Guerrero, J C Villa-Guzmán, R Acosta-Guerrero, et al.
Journal of Biological Regulators and Homeostatic Agents|October 5, 2019
Pseudovitelliform maculopathy secondary to BRAF and MEK inhibitors in a patient with metastasic melanomaC Alba-Linero, C Rocha De Lossada, A S Delgado-Fernández, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic MelanomaA Arance, M-A Berciano-Guerrero, J Guo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 26, 2020
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practiceE Pérez-Ruiz, J Jiménez-Castro, M-A Berciano-Guerrero, et al.
Pageof 1